clro-20220331.htm
2 false false CLEARONE INC 0000840715 clro --12-31 false true Non-accelerated Filer 2022 Q1 false DE UT true 0000840715 2021-03-31 0000840715 2020-04-18 2020-04-18 0000840715 2022-01-01 2022-03-31 0000840715 2021-01-01 2021-03-31 0000840715 2020-12-31 0000840715 2022-03-31 0000840715 us-gaap:WarrantMember us-gaap:CommonStockMember 2019-12-17 0000840715 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember srt:MaximumMember 2019-12-17 2019-12-17 0000840715 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2019-12-17 2019-12-17 0000840715 us-gaap:ConvertiblesAndBondsWithWarrantsAttachedMember 2022-01-01 2022-03-31 0000840715 us-gaap:ConvertibleDebtMember 2019-12-17 2019-12-17 0000840715 us-gaap:ConvertiblesAndBondsWithWarrantsAttachedMember 2019-12-17 2019-12-17 0000840715 us-gaap:RetainedEarningsMember 2020-12-31 0000840715 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000840715 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-12-31 0000840715 us-gaap:RetainedEarningsMember 2021-03-31 0000840715 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000840715 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000840715 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000840715 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2019-12-17 0000840715 us-gaap:ConvertibleDebtMember srt:MaximumMember 2019-12-17 2019-12-17 0000840715 us-gaap:CommonStockMember us-gaap:BeneficialOwnerMember 2019-12-17 2019-12-17 0000840715 us-gaap:ConvertiblesAndBondsWithWarrantsAttachedMember us-gaap:CommonStockMember 2019-12-17 0000840715 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-03-31 0000840715 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000840715 clro:EuropeAndAfricaMember 2022-01-01 2022-03-31 0000840715 clro:AsiaMiddleEastAndAustraliaMember 2022-01-01 2022-03-31 0000840715 srt:AmericasMember 2022-01-01 2022-03-31 0000840715 clro:VideoProductsMember 2022-01-01 2022-03-31 0000840715 clro:MicrophonesMember 2022-01-01 2022-03-31 0000840715 clro:AudioConferencingMember 2022-01-01 2022-03-31 0000840715 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000840715 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000840715 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-03-31 0000840715 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-03-31 0000840715 srt:MaximumMember clro:ProprietarySoftwareMember 2022-01-01 2022-03-31 0000840715 srt:MinimumMember clro:ProprietarySoftwareMember 2022-01-01 2022-03-31 0000840715 srt:MaximumMember us-gaap:TradeNamesMember 2022-01-01 2022-03-31 0000840715 srt:MinimumMember us-gaap:TradeNamesMember 2022-01-01 2022-03-31 0000840715 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000840715 clro:EuropeAndAfricaMember 2021-01-01 2021-03-31 0000840715 clro:AsiaMiddleEastAndAustraliaMember 2021-01-01 2021-03-31 0000840715 srt:AmericasMember 2021-01-01 2021-03-31 0000840715 clro:VideoProductsMember 2021-01-01 2021-03-31 0000840715 clro:MicrophonesMember 2021-01-01 2021-03-31 0000840715 clro:AudioConferencingMember 2021-01-01 2021-03-31 0000840715 us-gaap:LoansPayableMember 2020-04-18 2020-04-18 0000840715 us-gaap:LoansPayableMember 2020-04-18 0000840715 clro:PatentsAndTechnologicalKnowHowMember srt:MinimumMember 2022-01-01 2022-03-31 0000840715 clro:PatentsAndTechnologicalKnowHowMember srt:MaximumMember 2022-01-01 2022-03-31 0000840715 us-gaap:ConvertiblesAndBondsWithWarrantsAttachedMember 2021-01-01 2021-03-31 0000840715 us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0000840715 us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-03-31 0000840715 us-gaap:TradeNamesMember 2022-03-31 0000840715 clro:PatentsAndTechnologicalKnowHowMember 2022-03-31 0000840715 clro:ProprietarySoftwareMember 2022-03-31 0000840715 us-gaap:OtherIntangibleAssetsMember 2022-03-31 0000840715 stpr:FL srt:IndustrialPropertyMember 2022-03-31 0000840715 srt:OfficeBuildingMember stpr:UT 2022-03-31 0000840715 stpr:TX srt:OfficeBuildingMember 2022-03-31 0000840715 country:IN srt:OfficeBuildingMember 2022-03-31 0000840715 stpr:UT srt:WarehouseMember 2022-03-31 0000840715 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-03-31 0000840715 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000840715 us-gaap:RetainedEarningsMember 2022-03-31 0000840715 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0000840715 us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0000840715 us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0000840715 us-gaap:MeasurementInputExpectedDividendRateMember 2022-03-31 0000840715 us-gaap:ConvertibleNotesPayableMember 2022-03-31 0000840715 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0000840715 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0000840715 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0000840715 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-03-31 0000840715 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-03-31 0000840715 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-03-31 0000840715 us-gaap:FairValueInputsLevel1Member 2022-03-31 0000840715 us-gaap:FairValueInputsLevel2Member 2022-03-31 0000840715 us-gaap:FairValueInputsLevel3Member 2022-03-31 0000840715 us-gaap:MajorityShareholderMember us-gaap:BridgeLoanMember us-gaap:NotesPayableOtherPayablesMember 2021-07-02 0000840715 us-gaap:BridgeLoanMember 2021-07-02 0000840715 us-gaap:BridgeLoanMember 2021-07-01 2021-07-02 0000840715 us-gaap:MajorityShareholderMember us-gaap:BridgeLoanMember us-gaap:NotesPayableOtherPayablesMember 2021-07-01 2021-07-02 0000840715 us-gaap:CommonStockMember 2020-09-13 0000840715 us-gaap:CommonStockMember 2020-09-13 2020-09-13 0000840715 us-gaap:CommonStockMember 2021-09-12 0000840715 us-gaap:CommonStockMember 2021-09-12 2021-09-12 0000840715 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0000840715 2021-12-31 0000840715 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-12-31 0000840715 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000840715 us-gaap:RetainedEarningsMember 2021-12-31 0000840715 clro:LitigationForIntellectualPropertyInfringementMember 2016-01-01 2022-03-31 0000840715 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000840715 us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0000840715 us-gaap:TradeNamesMember 2021-12-31 0000840715 clro:PatentsAndTechnologicalKnowHowMember 2021-12-31 0000840715 clro:ProprietarySoftwareMember 2021-12-31 0000840715 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0000840715 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000840715 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000840715 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000840715 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0000840715 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0000840715 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0000840715 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000840715 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000840715 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000840715 us-gaap:SubsequentEventMember us-gaap:LoansPayableMember 2022-04-29 0000840715 us-gaap:SubsequentEventMember us-gaap:LoansPayableMember 2022-04-29 2022-04-29 0000840715 us-gaap:SubsequentEventMember us-gaap:LoansPayableMember 2022-04-01 2022-06-30 0000840715 clro:SecuritiesPurchaseAgreementMember us-gaap:MajorityShareholderMember us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2022-01-04 0000840715 us-gaap:MajorityShareholderMember us-gaap:BridgeLoanMember 2022-01-04 0000840715 us-gaap:MajorityShareholderMember us-gaap:BridgeLoanMember 2022-01-04 2022-01-04 0000840715 us-gaap:CommonStockMember 2022-03-31 0000840715 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-01-03 2022-01-31 0000840715 2022-05-18 xbrli:shares xbrli:pure utr:D utr:sqft iso4217:USD iso4217:USD xbrli:shares

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period _______ to _______

 

Commission file number:001-33660

CLEARONE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

87-0398877

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. employer identification number)

 

 

 

5225 Wiley Post Way, Suite 500, Salt Lake City, Utah

 

84116

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (801) 975-7200

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading Symbol(s)

  

Name of each exchange on which registered

Common Stock, $0.001

 

CLRO

 

The NASDAQ Capital Market

 

Indicate by check whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Larger Accelerated Filer

Accelerated Filer  

Non-Accelerated Filer

Smaller Reporting Company

 

Emerging Growth Company  


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes No


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

The number of shares of ClearOne common stock outstanding as of May 18, 2022 was 23,948,587

 CLEARONE, INC.

QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2022

 

INDEX




PART I - FINANCIAL INFORMATION



Item 1. Financial Statements 3




Unaudited Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 3




Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2022 and 2021 4




Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 5




Unaudited Notes to Condensed Consolidated Financial Statements 7



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19



Item 3. Quantitative and Qualitative Disclosures About Market Risk 26



Item 4. Controls and Procedures 26




PART II - OTHER INFORMATION



Item 1. Legal Proceedings 27



Item 1A. Risk Factors 27



Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27



Item 3. Defaults Upon Senior Securities 27



Item 4. Mine Safety Disclosures 27



Item 5. Other Information 27



Item 6. Exhibits 28

 

 

 

 

 

CLEARONE, INC

(Dollars in thousands, except par value)

 

 

 

March 31, 2022

 

 

December 31, 2021

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,422

 

 

$

1,071

 

Marketable securities

 

 

398

 

 

 

1,790

 

Receivables, net of allowance for doubtful accounts of $326 and $326, respectively

 

 

5,077

 

 

 

4,991

 

Inventories, net

 

 

9,865

 

 

 

10,033

 

Income tax receivable

7,540


7,535

Prepaid expenses and other assets

 

 

3,370

 

 

 

4,021

 

Total current assets

 

 

27,672

 

 

 

29,441

 

Long-term marketable securities

 

 

542

 

 

 

1,220

 

Long-term inventories, net

 

 

3,210

 

 

 

3,567

 

Property and equipment, net

 

 

676

 

 

 

744

 

Operating lease - right of use assets, net

 

 

1,383

 

 

 

1,537

 

Intangibles, net

 

 

24,675

 

 

 

25,086

 

Other assets

 

 

4,596

 

 

 

4,597

 

Total assets

 

$

62,754

 

 

$

66,192

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

4,125

 

 

$

5,388

 

Accrued liabilities

 

 

2,826

 

 

 

2,549

 

Deferred product revenue

 

 

46

 

 

 

54

 

Short-term debt

1,336


3,481

Total current liabilities

 

 

8,333

 

 

 

11,472

 

Long-term debt, net

 

 

1,359

 

 

 

1,535

 

Operating lease liability, net of current

 

 

871

 

 

 

1,026

 

Other long-term liabilities

 

 

655

 

 

 

655

 

Total liabilities

 

 

11,218

 

 

 

14,688

 

 

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common stock, par value $0.001, 50,000,000 shares authorized, 23,948,587 and 22,410,126 shares issued and outstanding, respectively

 

 

24

 

 

 

22

 

Additional paid-in capital

 

 

74,831

 

 

 

72,795

 

Accumulated other comprehensive loss

 

 

(280

)

 

 

(241

)

Accumulated deficit

 

 

(23,039

)

 

 

(21,072

)

Total shareholders' equity

 

 

51,536

 

 

 

51,504

 

Total liabilities and shareholders' equity

 

$

62,754

 

 

$

66,192

 

 

See accompanying notes

 

 

CLEARONE, INC.

COMPREHENSIVE LOSS

(Dollars in thousands, except per share amounts)

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Revenue

 

$

7,545

 

 

$

7,038

 

Cost of goods sold 

 

 

4,729

 

 

 

4,035

 

Gross profit

 

 

2,816

 

 

 

3,003

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

Sales and marketing

 

 

1,560

 

 

 

1,573

 

Research and product development

 

 

1,353

 

 

 

1,274

 

General and administrative

 

 

1,756

 

 

 

1,680

 

Total operating expenses

 

 

4,669

 

 

 

4,527

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(1,853

)

 

 

(1,524

)

 

 

 

 

 

 

 

 

 

Interest expense

(101 )

(112 )

Other income, net

 

 

3

 

 

(5

)

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(1,951

)

 

 

(1,641

)

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

16

 

 

 

14

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(1,967

)

 

$

(1,655

)

 

 

 

 

 

 

 

 

 

Basic weighted average shares outstanding

 

 

23,897,305

 

 

 

18,775,773

 

Diluted weighted average shares outstanding

 

 

23,897,305

 

 

 

18,775,773

 

 

 

 

 

 

 

 

 

 

Basic loss per share

 

$

(0.08

)

 

$

(0.09

)

Diluted loss per share

 

$

(0.08

)

 

$

(0.09

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

Net loss

 

$

(1,967

)

 

$

(1,655

)

Unrealized gain (loss) on available-for-sale securities, net of tax

 

 

(28

)

 

 

(2

)

Change in foreign currency translation adjustment

 

 

(11

)

 

 

(12

)

Comprehensive loss

 

$

(2,006

)

 

$

(1,669

)

 

See accompanying notes

 

 

CLEARONE, INC.

(Dollars in thousands, except per share amounts)

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(1,967

)

 

$

(1,655

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization expense

 

 

794

 

 

 

661

 

Amortization of right-of-use assets

 

 

154

 

 

 

149

 

Share-based compensation expense

 

 

36

 

 

 

31

 

Change of inventory to net realizable value

 

 

 

 

 

375

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Receivables

 

 

(86

)

 

 

264

Inventories

 

 

525

 

 

 

736

 

Prepaid expenses and other assets

 

 

651

 

 

265

Accounts payable

 

 

(1,263

)

 

 

(1,043

)

Accrued liabilities

 

 

286

 

 

446

Income taxes receivable

 

 

(5

)

 

 

(43

)

Deferred product revenue

 

 

(8

)

 

 

(45

)

Operating lease liabilities

 

 

(160

)

 

 

(154

)

Net cash used in operating activities

 

 

(1,043

)

 

 

(13

)

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(8

)

 

 

(7

)

Purchase of intangibles

 

 

(70

)

 

 

(71

)

Capitalized patent defense costs

 

 

(189

)

 

 

(1,678

)

Proceeds from maturities and sales of marketable securities

 

 

2,042

 

 

 

413

 

Purchases of marketable securities

 

 

 

 

(310

)

Net cash provided by (used in) investing activities

 

 

1,775

 

 

(1,653

)

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Net proceeds from equity-based compensation programs

 

 

2

 

 

 

4

 

Principal payments of long-term debt

(370 )

(90 )

Net cash provided by financing activities

 

 

(368

)

 

 

(86

)

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

 

(13

)

 

 

(17

)

 

 

 

 

 

 

 

 

 

Net increase in cash and cash equivalents 

 

 

351

 

 

(1,769

)

Cash and cash equivalents at the beginning of the period

 

 

1,071

 

 

 

3,803

 

Cash and cash equivalents at the end of the period 

 

$

1,422

 

 

$

2,034

 

  

See accompanying notes

 



 CLEARONE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands, except per share amounts)

 

The following is a summary of supplemental cash flow activities:

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Cash paid for income taxes

 

$

26

 

 

$

43

 

Cash paid for interest 51 50

 

See accompanying notes

 


CLEARONE, INC.

(Unaudited - Dollars in thousands, except per share amounts)

  

1. Business Description, Basis of Presentation and Significant Accounting Policies

 

Business Description:

 

ClearOne, Inc., together with its subsidiaries (collectively, “ClearOne” or the “Company”), is a global market leader enabling conferencing, collaboration, and AV streaming solutions for voice and visual communications. The performance and simplicity of our advanced, comprehensive solutions offer unprecedented levels of functionality, reliability and scalability.

 

Basis of Presentation:

 

The fiscal year for ClearOne is the twelve months ending on December 31. The condensed consolidated financial statements include the accounts of ClearOne and its subsidiaries. All significant inter-company accounts and transactions have been eliminated.

 

These accompanying interim unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and are not audited. Certain information and footnote disclosures that are usually included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been either condensed or omitted in accordance with SEC rules and regulations. The accompanying condensed consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial position as of March 31, 2022 and December 31, 2021, the results of operations for the three months ended March 31, 2022 and 2021, and the cash flows for the three months ended March 31, 2022 and 2021. The results of operations for the three months ended March 31, 2022 and 2021 are not necessarily indicative of the results for a full-year period. These interim unaudited condensed consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC.

 

Significant Accounting Policies:

 

The significant accounting policies were described in Note 1 to the audited consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2021. There have been no changes to these policies during the March 31, 2022 that are of significance or potential significance to the Company.


Recent accounting pronouncements: The Company has determined that recently issued accounting standards will not have a material impact on its consolidated financial position, results of operations or cash flows.


Liquidity:

 

As of March 31, 2022, our cash and cash equivalents were approximately $1,422 compared to $1,071 as of December 31, 2021. Our working capital was $19,339 as of March 31, 2022. Net cash used in operating activities was $1,043 for the three months ended March 31, 2022, an increase 1,030 from $13 of cash used in activities in the three months ended March 31, 2022.

The Company is currently pursuing all available legal remedies to defend its strategic patents from infringement. The Company has already spent approximately $28,345 from 2016 through March 31, 2022 towards this litigation and may be required to spend more to continue its legal defense.  

 

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited - Dollars in thousands, except per share amounts)

  

The Company has been actively engaged in preserving cash by suspending our dividend program and allowing our share repurchase program to expire in 2018 and implementing company-wide cost reduction measures. The company has also raised additional capital in 2019 by issuing senior convertible notes, in 2020 by borrowing through the CARES Act Paycheck Protection Program and issuing common stock and warrants and in 2021 by issuing short-term notes and issuing common stock and warrants. In January 2022, the Company issued $2,000 in common stock as consideration for the cancellation and termination of the short-term notes. In addition, we have been generating additional cash as our inventory levels are brought down to historical levels.


The Company also believes that the Company's core strategies of product innovation and prudent cost management will bring the company back to profitability in the future. The Company believes, although there can be no assurance, that all of these measures and effective management of working capital will provide the liquidity needed to meet our operating needs through at least May 19, 2023. We also believe that its strong portfolio of intellectual property and its solid brand equity in the market will enable it to raise additional capital if and when needed to meet our short and long-term financing needs; however, there can be no assurance that, if needed, we will be successful in obtaining the necessary funds through equity or debt financing. If the Company needs additional capital and is unable to secure financing, it may be required to further reduce expenses, delay product development and enhancement, or revise its strategy regarding ongoing litigation.

 

2. Revenue Information 

 

The following table disaggregates the Company’s revenue into primary product groups:

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Audio conferencing

 

$

3,176

 

 

$

2,835

 

Microphones

 

 

2,928

 

 

 

2,350

 

Video products

 

 

1,441

 

 

 

1,853

 

 

 

$

7,545

 

 

$

7,038

 

 

The following table disaggregates the Company’s revenue into major regions:


 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

North and South America

 

$

3,776

 

 

$

3,524

 

Asia Pacific (includes Middle East, India and Australia)

 

 

2,074

 

 

 

2,226

 

Europe and Africa

 

 

1,695

 

 

 

1,288

 

 

 

$

7,545

 

 

$

7,038

 

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited - Dollars in thousands, except per share amounts)


3. Loss Per Share

 

Loss per common share is computed based on the weighted-average number of common shares outstanding and, when appropriate, dilutive potential common stock outstanding during the period. Stock options, warrants and convertible portion of senior convertible notes are considered to be potential common stock. The computation of diluted earnings (loss) per share does not assume exercise or conversion of securities that would have an anti-dilutive effect. 

 

Basic earnings (loss) per common share is the amount of net earnings (loss) for the period available to each weighted-average share of common stock outstanding during the reporting period. Diluted earnings (loss) per common share is the amount of earnings (loss) for the period available to each weighted-average share of common stock outstanding during the reporting period and to each share of potential common stock outstanding during the period, unless inclusion of potential common stock would have an anti-dilutive effect.



The following table sets forth the computation of basic and diluted earnings (loss) per common share:

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(1,967

)

 

$

(1,655

)

Denominator:

 

 

 

 

 

 

 

 

Basic weighted average shares outstanding

 

 

23,897,305

 

 

 

18,775,773

 

Dilutive common stock equivalents using treasury stock method

 

 

 

 

 

 

Diluted weighted average shares outstanding

 

 

23,897,305

 

 

 

18,775,773

 

 

 

 

 

 

 

 

 

 

Basic loss per common share

 

$

(0.08

)

 

$

(0.09

)

Diluted loss per common share

 

$

(0.08

)

 

$

(0.09

)

 

 

 

 

 

 

 

 

 

Weighted average options, warrants and convertible portion of senior convertible notes outstanding

 

 

7,062,673

 

 

 

3,636,117

 

Anti-dilutive options, warrants and convertible portion of senior convertible notes not included in the computation

 

 

7,062,673

 

 

 

3,636,117

 

 



UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited - Dollars in thousands, except per share amounts)

 

4. Marketable Securities

 

The Company has classified its marketable securities as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on marketable security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned.

 

The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of securities as of March 31, 2022 and December 31, 2021 were as follows:

 

 

 

Amortized cost

 

 

Gross unrealized holding gains

 

 

Gross unrealized holding losses

 

 

Estimated fair value

 

March 31, 2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate bonds and notes

 

$

511

 

 

$

1

 

 

$

(13)

 

$

499

 

Municipal bonds

 

 

454

 

 

 

 

 

 

(13)

 

 

 

441

 

Total available-for-sale securities

 

$

965

 

 

$

1

 

 

$

(26)

 

$

940

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate bonds and notes

 

$

1,434

 

 

$

8

 

 

$

(2

)

 

$

1,440

 

Municipal bonds

 

 

1,573

 

 

 

 

 

 

(3

)

 

 

1,570

 

Total available-for-sale securities

 

$

3,007

 

 

$

8

 

 

$

(5

)

 

$

3,010

 

 

 Maturities of marketable securities classified as available-for-sale securities were as follows as of March 31, 2022:

 

 

 

Amortized cost

 

 

Estimated fair value

 

Due within one year

 

$

402

 

 

$

398

 

Due after one year through five years

 

 

563

 

 

 

542

 

Due after five years

 

 

 

 

 

 

Total available-for-sale securities

 

$

965

 

 

$

940

 



UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited - Dollars in thousands, except per share amounts)

 

Debt securities in an unrealized loss position as of March 31, 2022 were not deemed impaired at acquisition and subsequent declines in fair value are not deemed attributed to declines in credit quality. Management believes that it is more likely than not that the securities will receive a full recovery of par value, although there can be no assurance that such recovery will occur. The available-for-sale marketable securities with continuous gross unrealized loss position for less than 12 months and 12 months or greater and their related fair values were as follows:

 

 

 

Less than 12 months

 

 

More than 12 months

 

 

Total

 

 

 

Estimated fair value

 

 

Gross unrealized holding losses

 

 

Estimated fair value

 

 

Gross unrealized holding losses

 

 

Estimated fair value

 

 

Gross unrealized holding losses

 

As of March 31, 2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate bonds and notes

 

$

254

 

 

$

8

 

$

144

 

 

$

5

 

 

$

398

 

 

$

13

Municipal bonds

 

 

292

 

 

 

11

 

 

 

150

 

 

 

2

 

 

 

442

 

 

 

13

 

Total

 

$

546

 

 

$

19

 

$

294

 

 

$

7

 

 

$

840

 

 

$

26

 

Debt securities in an unrealized loss position as of March 31, 2022 were not deemed impaired at acquisition and subsequent declines in fair value are not deemed attributed to declines in credit quality. Management believes that it is more likely than not that the securities will receive a full recovery of par value, although there can be no assurance that such recovery will occur.


5. Intangible Assets

 

Intangible assets as of March 31, 2022 and December 31, 2021 consisted of the following:

 

 

 

Estimated useful lives (years)

 

 

March 31, 2022

 

 

December 31, 2021

 

Tradename

 

 5

to

7

 

 

$

555

 

 

$

555

 

Patents and technological know-how

 

10

 to

20

 

 

 

33,812

 

 

 

33,553

 

Proprietary software

 

 3

to

15

 

 

 

2,981

 

 

 

2,981

 

Other

 

 3

to

5

 

 

 

323

 

 

 

323

 

Total intangible assets

 

 

 

 

 

 

 

37,671

 

 

 

37,412

 

Accumulated amortization

 

 

 

 

 

 

 

(12,996

)

 

 

(12,326

)

Total intangible assets, net

 

 

 

 

 

 

$

24,675

 

 

$

25,086

 

 

The amortization of intangible assets for the three months ended March 31, 2022 and 2021 was as follows: 

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Amortization of intangible assets

 

$

670

 

 

$

511

 

 

The estimated future amortization expense of intangible assets is as follows:

 

Years ending December 31,

 

Amount

 

2022 (Remainder)

 

$

2,030

 

2023

 

 

2,700

 

2024

 

 

2,436

 

2025

 

 

2,375

 

2026

 

 

2,375

 

Thereafter

 

 

12,759

 

Total

 

$  

24,675

 

 

 

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited - Dollars in thousands, except per share amounts) 


6. Inventories

 

Inventories, net of reserves, as of March 31, 2022 and December 31, 2021 consisted of the following:

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Current:

 

 

 

 

 

 

 

 

Raw materials

 

$

3,821

 

 

$

4,085

 

Finished goods

 

 

6,044

 

 

 

5,948

 

 

 

$

9,865

 

 

$

10,033

 

 

 

 

 

 

 

 

 

 

Long-term:

 

 

 

 

 

 

 

 

Raw materials

 

$

1,576

 

 

$

1,980

 

Finished goods

 

 

1,634

 

 

 

1,587

 

 

 

$

3,210

 

 

$

3,567

 

  

Long-term inventory represents inventory held in excess of our current (next 12 months) requirements based on our recent sales and forecasted level of sales. We expect to sell the above inventory, net of reserves, at or above the stated cost and believe that no loss will be incurred on its sale, although there can be no assurance of the timing or amount of any sales. 

 

Net loss incurred on valuation of inventory at lower of cost or market value and write-off of obsolete inventory for the three months ended March 31, 2022 and 2021 was as follows:

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Net loss incurred on valuation of inventory at lower of cost or market value and write-off of obsolete inventory

 

$

 

 

$

375

 

 

7. Leases

 

Rent expense is recognized on a straight-line basis over the period of the lease taking into account future rent escalation and holiday periods. 

 

Rent expense for the three months ended March 31, 2022 and 2021 was as follows: 

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Rent expense

 

$

179

 

 

$

184

 

The Company occupies a 1,350 square-foot facility in Gainesville, Florida under the terms of an operating lease expiring in February 2023The Gainesville facility is used primarily to support the Company's research and development activities. 

 

The Company occupies a 21,443 square-foot facility in Salt Lake City, Utah under the terms of an operating lease expiring in March 2024, with an option to extend for additional five years. The facility supports the Company's principal administrative, sales, marketing, customer support, and research and product development activities.  

 

The Company occupies a 950 square-foot facility in Austin, Texas under the terms of an operating lease expiring in October 2022. This facility supports the Company's sales, marketing, customer support, and research and development activities.

 


UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited - Dollars in thousands, except per share amounts)


The Company occupies a 6,175 square-foot facility in Chennai, India under the terms of an operating lease expiring in August 2023. This facility supports the Company's administrative, marketing, customer support, and research and product development activities.

 

The Company occupies a 40,000 square-foot warehouse in Salt Lake City, Utah under the terms of an operating lease expiring in April 2025, which serves as the Company's primary inventory fulfillment and repair center.  


Supplemental cash flow information related to leases was as follows: 

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Cash paid for amounts included in the measurement of lease liabilities

 



 

 



 

Operating cash flows from operating leases
$ (183 )
$ (184 )
Right-of-use assets obtained in exchange for lease obligations:







Operating leases
$

$

 

Supplemental balance sheet information related to leases was as follows:

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Operating lease right-of-use assets

 

$

 1,383

 

 

 $

 1,537

 


 








Current portion of operating lease liabilities, included in accrued liabilities
$ 618

$ 623

Operating lease liabilities, net of current portion

 

 

871

 

 

 

1,026

 

Total operating lease liabilities

 

$

1,489

 

 

$

1,649

 

 

 

 

 

 

 

 

 

 

Weighted average remaining lease term for operating leases (in years) 

2.42


2.64
Weighted average discount rate for operating leases

5.89 %

5.87 %

  

The following represents maturities of operating lease liabilities as of March 31, 2022:

 

Years ending December 31,

 

 

 

 

2022 (Remainder)

 

$

520

 

2023

 

 

671

 

2024

 

 

343

 

2025

 

 

69

 

2026

 

 

 

Total lease payments

 

 

1,603

 

Less: Imputed interest

 

 

(114

)

Total

 

$

1,489

 


 

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited - Dollars in thousands, except per share amounts)

 

8. Shareholders' Equity

 

 

 

Three months ended March 31,

 

 

 

2022

 

 

2021

 

Common stock and additional paid-in capital

 

 

 

 

 

 

 

 

Balance, beginning of period

 

$

72,818

 

 

$

63,378

 

Issuance of common stock and warrants, net

                2,000


         

Share-based compensation expense

 

 

35

 

 

 

31

 

Proceeds from employee stock purchase plan

 

 

2

 

 

 

4

 

Balance, end of period

 

$

74,855

 

 

$

63,413

 

 

 

 

 

 

 

 

 

 

Accumulated other comprehensive loss

 

 

 

 

 

 

 

 

Balance, beginning of period

 

$

(241

)

 

$

(186

)

Unrealized loss on available-for-sale securities, net of tax 

 

 

(28

)

 

 

(2

)

Foreign currency translation adjustment

 

 

(11

)

 

 

(12

)

Balance, end of period

 

$

(280

)

 

$

(200

)

 

 

 

 

 

 

 

 

 

Accumulated deficit

 

 

 

 

 

 

 

 

Balance, beginning of period

 

$

(21,072

)

 

$

(13,378

)

Net loss

 

 

(1,967

)

 

 

(1,655

)

Balance, end of period

 

$

(23,039

)

 

$

(15,033

)

 

 

 

 

 

 

 

 

 

Total shareholders' equity

 

$

51,536

 

 

$

48,180

 

 

Issue of Common Stock and Warrants


On September 13, 2020, the Company entered into a securities purchase agreement with certain purchasers named therein, pursuant to which the Company issued and sold in a registered direct offering 2,116,050 shares of the Company's common stock, par value $0.001 per share at an offering price of $2.4925 per share. The Company received gross proceeds of approximately $5,275 and net proceeds $4,764 after deducting placement agent fees and related offering expenses. In a concurring private placement, the Company also issued to the same purchasers warrants exercisable for an aggregate of 1,058,025 shares of common stock at an exercise price of $2.43 per share. Each warrant became immediately exercisable and will expire five years from the issuance date. 


On  September 12, 2021, the Company entered into a securities purchase agreement with certain purchasers named therein, pursuant to which the Company issued 3,623,189 shares of the Company's common stock, par value $0.001 per share at an offering price of $2.76 per share. The Company received gross proceeds of approximately $10,000 and net proceeds of $9,288 after deducting placement agent fees and related offering expenses. In a concurring private placement the Company also issued to the same purchasers warrants exercisable for an aggregate of 3,623,189 shares of common stock at an exercise price of $2.76 per share. Each warrant became immediately exercisable and will expire on March 15, 2027.


On January 4, 2022, the Company entered into a Securities Purchase Agreement with Edward D. Bagley, an affiliate of the Company, pursuant to which the Company agreed to issue and sell, in a private placement 1,538,461 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, at a purchase price of $1.30 per share of Common Stock. The consideration for the Shares is the cancellation and termination of Mr.Bagley’s outstanding bridge loan to the Company in the principal amount of $2,000,000 originally issued on July 2, 2021 and amended and restated on September 11, 2021. Mr. Bagley is an affiliate of the Company and the Company’s single largest stockholder. 



UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited - Dollars in thousands, except per share amounts)


9. Debt

Senior Convertible Notes and Warrants 

On December 17, 2019, the Company completed the issuance and sale of $3,000 aggregate principal amount of secured convertible notes of the Company (the “Notes”) and warrants (the “Warrants”) to purchase 340,909 shares of common stock, par value $0.001 per share of the Company (the “Common Stock”), in a private placement transaction. The Notes and Warrants were issued and sold to Edward D. Bagley, an affiliate of the Company, on the terms and conditions of a Note Purchase Agreement dated December 8, 2019 between the Company, certain subsidiary guarantors of the Company, and Mr. Bagley. Mr. Bagley was the beneficial owner of approximately 46.6% of the Company’s issued and outstanding shares of Common Stock at the time that the Notes and Warrants were issued to him. 

 

The Notes will mature on December 17, 2023 (the “Maturity Date”) and will accrue interest at a variable rate adjusted on a quarterly basis and equal to two and one-half percent (2.5%) over the greater of (x) five and one-quarter percent (5.25%) and (y) the Prime Rate as published in the Wall Street Journal (New York edition) as of the beginning of such calendar quarter.  The Notes may be converted into shares of the Company’s Common Stock at any time at the election of Mr. Bagley at an initial conversion price of $2.11 per share (the “Conversion Price”), or 120% of the closing price of the Common Stock on December 6, 2019 as reported on the Nasdaq Capital Market. Also, the Company can cause a mandatory conversion of the Notes if the volume weighted average closing price of the Common Stock over 90 consecutive trading days exceeds 200% of the Conversion Price. In addition, the Notes may be redeemed by the Company for cash at any time after December 17, 2020 upon payment of the outstanding principal balance of the Notes and any unpaid and accrued interest.  The Company also is required to redeem the Notes upon the occurrence of a change in control of the Company.

The Warrants have an initial exercise price equal to $1.76, the closing price of the Common Stock on December 6, 2019 as reported on the Nasdaq Capital Market, and are exercisable until December 17, 2026.  The Warrants must be exercised for cash, unless at the time of exercise there is not a then effective registration statement for the resale of the shares of Common Stock issuable upon exercise of the Warrants, in which case the Warrants may be exercised via a cashless exercise feature that provides for net settlement of the shares of Common Stock issuable upon exercise. 

Concurrent with the issuance of the Notes and Warrants pursuant to the Note Purchase Agreement, the Company, the Guarantors and Mr. Bagley entered into a Guaranty and Collateral Agreement (the “Collateral Agreement”) pursuant to which the Company and the Guarantors granted Mr. Bagley a first priority lien interest in all of the Company’s assets as security for the Company’s performance of its obligations under the Notes and Warrants.

The net proceeds after original issue discount and issuance costs of $346 were approximately $2,654. The Company expects to use the proceeds from the sale of the Notes and Warrants for general corporate purposes and working capital. 

In accounting for the issuance of the Notes, the Company separated Notes and Warrants into liability and equity components. The carrying amount of Warrants, being an equity component, was first calculated using Black-Scholes method with the following assumptions:

 

Risk-free interest rate

1.82%

Expected life of warrants (years)

7

Expected price volatility

49.4%

Expected dividend yield

0%


The carrying amount of the Notes was then determined by deducting the fair value of the Warrants from the principal amount of the Notes. The carrying amount of the Notes was further separated into equity and liability components after separating the value of the conversion feature into an equity component and leaving the remaining value as liability. The equity component is not remeasured while the Notes and Warrants continue to meet the conditions for equity classification for equity components.

The original issue discount and issuance costs are netted against the liability. The following table represents the carrying value of Notes and Warrants:




UNAUDITED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts)


 

 

March 31, 2022

 

 

December 31, 2021

 

Liability component:

 

 

 

 

 

 

 

 

Principal

 

$

2,460

 

 

$

2,640

 

Less: debt discount and issuance costs, net of amortization

 

 

(450

)

 

 

(385

Net carrying amount

 

$

2,010

 

 

$

2,255

 

Equity component(1):

 

 

 

 

 

 

 

 

Warrants

 

$

318

 

 

$

318

 

Conversion feature

 

122

 

 

122

 

Net carrying amount

 

$

440

 

 

$

440

 










Current portion of liability component included under short-term debt
$ 765

$ 720
Long-term portion of liability component included under long-term debt

1,695


1,920
Liability component total
$ 2,460

$ 2,640

(1) Recorded on the condensed consolidated balance sheets as additional paid-in capital. 


Debt discount and issuance costs are amortized over the life of the note to interest expense using the effective interest method. During the three months ended March 31, 2022 and March 31, 2021 amortization of debt discount and issuance costs was $49 and $49, respectively. The following table represents schedule of maturities of principal amount contained in the Notes as of March 31, 2022:

Year ending December 31,

 

Principal Amount Maturing

 

2022 (Remainder)

 

$

540

 

2023

 

 

1,920

 

2024

 

 

 

2025

 

 

 

Total principal amount

 

$

2,460

 


Short-term Bridge Loan


On July 2, 2021, the Company obtained a bridge loan in the principal amount of $2,000 from Edward D. Bagley (the “Bridge Loan”), an affiliate of the Company. The Bridge Loan is evidenced by a promissory note dated July 2, 2021 (the “Note”) issued by the Company to Mr. Bagley.  The Note bears interests at a rate of 8.0% per annum, matures on the earlier to occur of (i) October 1, 2021 or (ii) within two business days of the Company’s receipt of its expected U.S. federal income tax refund, and contains other customary covenants and events of default. On September 11, 2021, the Company amended and restated the terms of the Bridge Loan to extend the latest maturity date from October 1, 2021 to January 3, 2022. All other terms and conditions of the Bridge Loan remained the same. This Bridge Loan of $2,000 is included under short-term debt. On January 4, 2022, the Company entered into a Securities Purchase Agreement with Edward D. Bagley, pursuant to which the Company agreed to issue and sell, in a private placement 1,538,461 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, at a purchase price of $1.30 per share of Common Stock. The consideration for the Shares is the cancellation and termination of Mr. Bagley’s outstanding bridge loan to the Company in the principal amount of $2,000,000 originally issued on July 2, 2021 and amended and restated on September 11, 2021. Mr. Bagley is an affiliate of the Company and the Company’s single largest stockholder.


Paycheck Protection Program Loan


On April 18, 2020, the Company, entered into a loan agreement with U.S. Bank National Association Bank, which provided for a loan in the principal amount of $1,499 (“PPP Loan”) pursuant to the Paycheck Protection Program under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The PPP Loan has a two-year term and bears interest at a rate of 1.0% per annum. Monthly principal and interest payments are deferred for approximately sixteen months after the date of disbursement.  


The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. The PPP Loan contains events of default and other provisions customary for a loan of this type. The Paycheck Protection Program provides that the Loans may be partially or wholly forgiven if the funds are used for certain qualifying expenses as described in the CARES Act. The Company intends to use the entire PPP Loan amount for qualifying expenses and to apply for forgiveness of the PPP Loan in accordance with the terms of the CARES Act.




UNAUDITED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts)


As further discussed in Note 11 - Subsequent Events, the PPP Loan and the interest associated with the loan have been forgiven by United States Small Business Administration ("SBA") effective April 29, 2022.


 

 

March 31, 2022

 

 

December 31, 2021

 

Current portion of the PPP Loan included under short-term debt
$ 571

$ 761
Long-term portion of the PPP Loan included under long-term debt





Liability component total
$ 571

$ 761

10. Fair Value Measurements

 

The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: 

 

Level 1 - Quoted prices in active markets for identical assets and liabilities.

 

Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. This category generally includes U.S. Government and agency securities; municipal securities; mutual funds and securities sold and not yet settled.

 

Level 3 - Unobservable inputs.

 

The Company’s financial instruments are valued using observable inputs. The following table sets forth the fair value of the financial instruments re-measured by the Company as of March 31, 2022 and December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

March 31, 2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate bonds and notes

 

$

 

 

$

499

 

 

$

 

 

$

499

 

Municipal bonds

 

 

 

 

 

441

 

 

 

 

 

 

441

 

Total

 

$

 

 

$

940

 

 

$

 

 

$

940

 

December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate bonds and notes

 

$

 

 

$

1,440

 

 

$

 

 

$

1,440

 

Municipal bonds

 

 

 

 

 

1,570

 

 

 

 

 

 

1,570

 

Total

 

$

 

 

$

3,010

 

 

$

 

 

$

3,010

 

 

11. Income Taxes

 

The current year loss did not result in income tax benefit due to recording a full valuation allowance against expected benefits. The valuation allowance was recorded as we concluded that it was more likely than not that our deferred tax assets were not realizable primarily due to the Company's recent pre-tax losses. Provision for income taxes for the three months ended March 31, 2022 represents income tax expense recorded for jurisdictions outside the United States. 


The Company had approximately $895 of uncertain tax positions as of March 31, 2022. Due to the inherent uncertainty of the underlying tax positions, it is not possible to forecast the payment of this liability for any particular year.

 


12. Subsequent events

 

The Company's Paycheck Protection Program Loan ("PPP Loan") under the CARES Act was forgiven by Small Business Administration effective April 29, 2022. With this forgiveness, the Company is not required to repay the principal amount of $1,499 and the interest of $31. The Company expects to receive $953 back that it had already paid towards principal and interest payments toward the PPP Loan. The Company will treat the forgiveness as extinguishment of debt in the quarter ended June 30, 2022 and will report the entire principal amount forgiven of $1,499 along with interest already accounted for of $27 as a gain on extinguishment of debt.


13. Commitments


We have manufacturing agreements with electronics manufacturing service (“EMS”) providers related to the outsourced manufacturing of our products. Certain manufacturing agreements establish annual volume commitments. We are also obligated to repurchase the Company-forecasted but unused materials. The Company has non-cancellable, non-returnable, and long-lead time commitments with its EMS providers and certain suppliers for inventory components that will be used in production. The Company’s purchase commitments under such agreements are approximately $4,850 as of March 31, 2022.

 

This report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements in this report, other than statements of historical fact, are forward-looking statements for purposes of these provisions, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. All forward-looking statements included in this report are made as of the date hereof and are based on information available to us as of such date. We assume no obligation to update any forward-looking statement. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “potential,” or “continue,” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are based upon reasonable assumptions at the time made, there can be no assurance that any such expectations or any forward-looking statement will prove to be correct. Our actual results will vary, and may vary materially, from those projected or assumed in the forward-looking statements. Future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, many of which we cannot predict with accuracy and some of which we might not anticipate, including, without limitation, product recalls and product liability claims; infringement of our technology or assertion that our technology infringes the rights of other parties; termination of supplier relationships, or failure of suppliers to perform; inability to successfully manage growth; delays in obtaining regulatory approvals or the failure to maintain such approvals; concentration of our revenue among a few customers, products or procedures; development of new products and technology that could render our products obsolete; market acceptance of new products; introduction of products in a timely fashion; price and product competition, availability of labor and materials, cost increases, and fluctuations in and obsolescence of inventory; volatility of the market price of our common stock; foreign currency fluctuations; changes in key personnel; work stoppage or transportation risks; integration of business acquisitions; and other factors referred to in our reports filed with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. All subsequent forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Additional factors that may have a direct bearing on our operating results are discussed in  Part II, Item 1A “Risk Factors” in this Quarterly Report on Form 10-Q and in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

BUSINESS OVERVIEW

 

ClearOne is a global Company that designs, develops and sells conferencing, collaboration, and AV networking solutions for voice and visual communications. The performance and simplicity of our advanced, comprehensive solutions offer a high level of functionality, reliability and scalability. We derive a major portion of our revenue from audio conferencing products and microphones by promoting our products in the professional audio-visual channel. We have extended our total addressable market from the installed audio conferencing market to adjacent complementary markets – microphones, video collaboration and AV networking. We have achieved this through strategic technological acquisitions as well as by internal product development.

 

In early January 2022, we introduced DIALOG® 10 USB, the industry's only pro-quality, single-channel wireless USB microphone system offering professional-quality audio with USB connectivity for webcasting and cloud-based collaboration. In March 2022, this new USB wireless mic system won the 2022 NSCA Excellence in Product Innovation Award. One of only seven winners in this prestigious award program, the DIALOG® 10 USB is the industry’s only pro-quality single-channel wireless microphone system with USB connectivity for webcasting and cloud-based collaboration such as Microsoft Teams, Zoom, WebEx, and GotoMeeting.


During January, at the Las Vegas Customer Electronics Show, CES 2022, the world’s most influential annual tech event, our home office Aura™ Xceed™ BMA was singled out for exceptional innovation with a CES Picks Award, presented by Residential Systems magazine.


In early February 2022, our Versa Lite CT, a USB audio-enabled Beamforming Ceiling Tile Microphone that brings cost-effective and superb professional conferencing audio to small- and mid-sized spaces received Google Meet certification. Google Meet ranks among the top 5 for growth in the cloud meetings and team collaboration market according to Frost & Sullivan.


In early February 2022, we were awarded a new patent for a beamforming microphone array system with distributed processing. This patent claims a ceiling tile microphone array that can be physically separated from the processors running the beamforming algorithm. It enables a single computing engine to run multiple beamforming algorithms for multiple microphone arrays, which can lower the overall system cost compared to an integrated design that is limited to a single computing engine with a single microphone array.  Later in the same month another ClearOne patent was granted which is related to beamforming microphone arrays with acoustic echo cancellation. The patent, titled “Band-Limited Beamforming Microphone Array with Acoustic Echo Cancellation," describes, among other things, a microphone array with one set of microphones used for beamforming, and one or more additional microphones that are not used for beamforming, but instead are used to enhance the audio performance of the microphone array.



MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

During the first three months of 2022, we continued our efforts, primarily through litigation, to stop the infringement of our strategic patents. We believe the decision by the U.S. District Court in August 2019 granting our request for a preliminary injunction to prevent Shure from manufacturing, marketing, and selling its competing ceiling microphone array in an infringing configuration is an incredibly valuable ruling for ClearOne and its business. The decision validates the strength and importance of ClearOne’s intellectual property rights, recognizes ClearOne’s innovations in this space, and stops Shure from further infringing the Graham patent (U.S. Patent No. 9,813,806) pending a full trial. Although there can be no assurance of any outcome of a full trial, we believe this ruling will help pave the way for ClearOne’s recovery from the immense harm inflicted by Shure's infringement of our valuable patents. However, we are not getting the full benefits of the Court’s extraordinary remedy in the form of the preliminary injunction granted against Shure with respect to infringement of our ’806 Patent as we believe that Shure is still infringing ClearOne’s patent. 

 

On September 1, 2020, the U.S. District Court of Northern Illinois held that "Shure has violated the preliminary injunction order and is found in contempt because it designed the MXA910-A in such a way that allows it to be easily installed flush in most ceiling grids”. The Court also opined that, “[t]he record is clear and convincing that Shure - through its design choices - violated the injunction order by allowing integrators to install the MXA910-A in the enjoined flush configuration.” Ultimately, the Court ordered that “Shure shall no longer manufacture, market, or sell the MXA910...”. ClearOne’s motion to accuse Shure’s MXA910-US of infringing the ’806 Patent is still pending with the Court.

 

Shure expanded the original litigation in the U.S. District Court of North Illinois to the District of Delaware, where Shure filed claims for patent infringement, including of a design patent, and trade libel against ClearOne. In May 2020 and January 2021, we secured an important pair of wins, defeating Shure’s requests first for a temporary restraining order and then a preliminary injunction, allowing us to continue selling our ground-breaking audio-conferencing products. In addition to defeating Shure’s requests for preliminary injunctive relief, we also obtained a stay of the proceedings with respect to the only other asserted patent. During November 2021, after a three-day jury trial, ClearOne obtained a complete victory against claims asserted by Shure, when the jury returned a verdict of no infringement and invalidated the asserted patent.


In February 2022 we claimed another legal victory over Shure. The Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (PTO) issued a final written decision confirming the patentability of all claims of ClearOne’s important U.S. Patent No. 10,728,653 (the “’653 Patent”). The ’653 Patent covers aspects of ClearOne’s revolutionary innovations in BMAs and relates to “a ceiling tile combined with [a] beamforming microphone array” that includes acoustic echo cancellation and “adaptive acoustic processing that automatically adjusts to a room configuration.” Shortly after the ’653 patent was issued in mid-2020, Shure initiated the case in yet another attempt to disrupt ClearOne’s patent rights, but the PTAB rejected each and every one of Shure’s seven challenges and is the latest in a long string of defeats for Shure. In 2019, the U.S. District Court for the Northern District of Illinois preliminarily enjoined Shure from infringing a different ClearOne patent, U.S. Patent No. 9,813,806, and then in 2020 held Shure in contempt of that injunction in case no. 17-cv-3078. In November 2021, a jury in a different court, the U.S. District Court for the District of Delaware, found a Shure design patent asserted against ClearOne to be invalid and not infringed.



MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


We also continued our programs to cut costs and to speed up product development that we believe will enable us to get back to a growth path.

 

Overall revenue increased by 7% in the first quarter of 2022 when compared to the first quarter of 2021, primarily due to a significant increase in revenues from microphones followed by an increase in revenues from audio conferencing products and partially offset by a decrease in revenues from video products.  Despite the negative impact of COVID-19 and the infringement of our patents by Shure on all professional installed products, our new solutions incorporating Beamforming Microphone Array Ceiling Tile ("BMA-CT") continued to result in overall Beamforming Microphone Array ("BMA") revenue to be significantly higher than last year. However, revenue from BMA products as well as from our pro audio products are still far below the levels prior to infringement of our patents. Our revenue is negatively impacted  due to on-going harm of infringement of ClearOne’s patents despite the preliminary injunction granted against Shure as we believe Shure continues to infringe certain of our patents and violates the preliminary injunction. The patent infringement also has negatively impacted directly the revenue from ClearOne’s other products not related to the infringed patents. Our revenue performance in 2022-Q1 was also impacted negatively due to the raw material supply shortages that have affected the global manufacturing of high tech products as well as due to logistics bottlenecks. Despite the negative impact of COVID-19 and the infringement of our patents by Shure on all professional installed products, our new solutions incorporating Beamforming Microphone Array Ceiling Tile ("BMA-CT") continued to result in overall Beamforming Microphone Array ("BMA") revenue to be significantly higher than last year. However, revenue from BMA products as well as from our pro audio products are still far below the levels prior to infringement of our patents. Our revenue is negatively impacted  due to on-going harm of infringement of ClearOne’s patents despite the preliminary injunction granted against Shure as we believe Shure continues to infringe certain of our patents and violates the preliminary injunction. The patent infringement also has negatively impacted directly the revenue from ClearOne’s other products not related to the infringed patents.  


Our gross profit margin decreased to 37.3% during the first quarter of 2022 from 42.7% during the first quarter of 2021. Net loss increased from $1.7 million in the first quarter of 2021 to $2.0 million in the first quarter of 2022The increase in net loss was mainly due to (a) decrease in absolute gross profit dollars as a result of reduced gross margin, and (b) increased amortization costs relating to our capitalized patent defense costs. 

 


MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Industry conditions

 

We operate in a very dynamic and highly competitive industry which is dominated on the one hand by a few players with respect to certain products like traditional video conferencing appliances while on the other influenced heavily by a fragmented reseller market consisting of numerous regional and local players. The industry is also characterized by venture capitalist funded start-ups and private companies willing to fund cumulative cash losses in order to gain market share and achieve certain non-financial goals. 

 

Economic conditions, challenges and risks

 

The audio-visual products market is characterized by intense competition and rapidly evolving technology. Our competitors vary within each product category. Our installed professional audio conferencing products, which is our flagship product category, continue to be ahead of the competition despite the reduction in revenues. Our strength in this space is largely due to our fully integrated suite of products consisting of DSP mixers, wide range of professional microphone products and video collaboration products. Despite our strong leadership position in the installed professional audio conferencing market, we face challenges to revenue growth due to the limited size of the market and pricing pressures from new competitors attracted to the commercial market due to higher margins.


Our video products and beamforming microphone arrays, especially BMA-CT and the newly introduced BMA 360 are critical to our long term growth. We face intense competition in this market from well-established market leaders as well as emerging players rich with marketing funds. We expect our strategy of combining curated audio solutions with our high quality professional cameras, and our high-end audio conferencing technology will generate high growth in the near future.


We derive a major portion of our revenue (approximately 51% for the year ended December 31, 2021) from international operations and expect this trend to continue in the future. Most of our revenue from outside the U.S. is billed in U.S. dollars and is not exposed to any significant currency risk. However, we are exposed to foreign exchange risk if the U.S. dollar is strong against other currencies as it will make U.S. Dollar denominated prices of our products less competitive. 


In December 2019, a novel strain of coronavirus (“COVID-19”) started spreading from China and was declared a pandemic. The COVID-19 pandemic caused severe global disruptions and had varying impact on our business. The installed audio conferencing market was negatively impacted due to lockdowns, postponement of projects and restrictions on installers to visit commercial sites. On the other hand, COVID-19 generated higher than normal demand for our video products and personal conferencing products due to the significant expansion of work-from-home market. The extent of COVID-19’s effect on our operational and financial performance keeps evolving and depends on multiple factors including the severity and infectiousness of current and future virus strains, effectiveness of vaccines especially on novel strains of COVID-19, government regulations, etc., all of which are uncertain and difficult to predict considering the rapidly evolving landscape. Supply chain disruptions resulting from COVID-19 have caused significant fluctuations in our costs of goods resulting in a reduction of our gross margins in 2021 and in the first quarter of 2022. We expect for these fluctuations to continue in 2022. If the pandemic continues to be a severe worldwide health crisis, the disease could have a material adverse effect on our business, results of operations, financial condition and cash flows and adversely impact the trading price of our common stock.

 

Deferred Product Revenue

 

Deferred product revenue decreased to $46 thousand on March 31, 2022 compared to $54 thousand on December 31, 2021.

 

A detailed discussion of our results of operations follows below.

 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Results of Operations for the three months ended March 31, 2022

 

The following table sets forth certain items from our unaudited condensed consolidated statements of operations for the three months ended March 31, 2022 (“2022-Q1”) and 2021 ("2021-Q1"), respectively, together with the percentage of total revenue which each such item represents:   


   

Three months ended March 31,


(dollars in thousands)  

2022

   

2021

    Change Favorable (Adverse) in %

Revenue

  $ 7,545     $ 7,038       7

Cost of goods sold

    4,729       4,035       (17 )

Gross profit

    2,816     3,003       (6 )

Sales and marketing

    1,560       1,573       1

Research and product development

    1,353       1,274       (6 )

General and administrative

    1,756       1,680       (5 )

Total operating expenses 

    4,669       4,527    
(3 )

Operating loss

    (1,853 )     (1,524 )     (22 )

Interest expense net of other income

    (98 )     (117 )     16

Loss before income taxes

    (1,951 )     (1,641 )     (19 )

Provision for income taxes

    16       14     (14 )

Net loss

  $ (1,967 )   $ (1,655 )     (19 )

 

Revenue

 

Our revenue increased to $7.5 million in 2022-Q1 compared to $7.0 million in 2021-Q1 primarily due to a 23% increase in microphones and a 13% increase in audio conferencing products partially offset by a 22% decrease in video products. Microphones growth continued to be led by our new solutions incorporating BMA-CT and BMA 360 while our traditional ceiling mics also enjoyed a significant revenue increase. Audio Conferencing category as a whole increased mainly due to a strong revenue performance of our professional mixers and personal audio conferencing products. Video products suffered declines in 2022-Q1 compared to 2021-Q1 due to lack of demand for video products. During the first quarter of 2022, revenues from Americas increased by 6% primarily due to increased revenues from USA despite significant revenue decreases  from Latin America and Canada, while revenues from Asia Pacific, including the Middle East, India and Australia decreased by 6% primarily due to overall decrease in revenues from all regions except India and China, and revenues from Europe and Africa increased by 33% primarily due to significant revenue increases from all parts of Europe except central Europe.  


We believe, although there can be no assurance, that we can sustain our revenue growth and return to generating operating profits through our strategic initiatives namely product innovation, cost reduction and defense of our intellectual property. 

 

Costs of Goods Sold and Gross Profit  

 

Cost of goods sold includes expenses associated with finished goods purchased from outsourced manufacturers, the repackaging of our products, our manufacturing and operations organization, property and equipment depreciation, warranty expense, freight expense, royalty payments, and the allocation of overhead expenses.


Our gross profit margin decreased from 42.7% during 2021-Q1 to 37.3% during 2022-Q1. The gross profit margin was negatively impacted due to increase in material costs due to continuing supply chain constraints, and increased freight and tariff costs, which were partially offset by the absence of inventory obsolescence costs in 2022-Q1. 

 


MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Our profitability in the near-term continues to depend significantly on our revenues from professional installed audio-conferencing products. We hold long-term inventory and if we are unable to sell our long-term inventory, our profitability might be affected by inventory write-offs and price mark-downs. Our long-term inventory includes approximately $0.6 million of wireless microphone-related finished goods and assemblies, $0.3 million of Converge Pro and Beamforming microphone array products, $0.1 million of network media streaming products, $0.6 million of video products, and about $1.7 million of raw materials that will be used primarily for manufacturing professional audio conferencing products. Any business changes that are adverse to these product lines could potentially impact our ability to sell our long-term inventory in addition to our current inventory.

 

Operating Expenses

 

Operating expenses include sales and marketing (“S&M”) expenses, research and product development (“R&D”) expenses and general and administrative (“G&A”) expenses. Total operating expenses were $4.7 million in  2022 Q1 compared to $4.5 million in 2021-Q1. The following contains a more detailed discussion of expenses related to sales and marketing, research and product development, general and administrative, and other items. 

Sales and Marketing - S&M expenses include selling, customer service, and marketing expenses such as employee-related costs, allocations of overhead expenses, trade shows, and other advertising and selling expenses.

 

S&M expenses in 2022-Q1 remained almost unchanged at $1.6 million when compared to 2021-Q1. The decrease in employment expenses and consultant expenses due to a reduction in the headcount were offset by an increase in employee travel and benefits expenses and increase in advertising expenses. 

  

Research and Product Development - R&D expenses include research and development, product line management, engineering services, and test and application expenses, including employee-related costs, outside services, expensed materials, depreciation, and an allocation of overhead expenses.

 

R&D expenses increased marginally to $1.4 million in 2022-Q1 compared to $1.3 million for 2021-Q1. The increase was primarily due to increases in R&D project expenses, legal expenses, and employee benefits, which were partially offset by reduction in employment expenses due to reduction in the headcount.

  

General and Administrative - G&A expenses include employee-related costs, professional service fees, allocations of overhead expenses, litigation costs, and corporate administrative costs, including costs related to finance and human resources teams.

 

G&A expenses increased marginally from $1.7 million in 2021-Q1 to $1.8 million in 2022-Q1. The increase was primarily due to increased amortization costs relating to our capitalized patent defense costs, which were partially offset by a reduction in legal expenses and consulting expenses.

  

Other income (expense), net

 

Other income (expense), net includes interest income and foreign currency changes. Other income remained immaterial during the first quarter of 2022 and 2021.

 

Interest expense almost remained unchanged at $0.1 million in 2022-Q1 when compared to 2021-Q1. 


Provision for income taxes

 

During the first quarters of 2022 and 2021, we did not recognize any benefit from the losses incurred due to setting up of a full valuation allowance. Provision for income taxes recognized in the first quarter of 2022 relates to foreign jurisdictions


 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of March 31, 2022, our cash and cash equivalents were approximately $1.4 million compared to $1.1 million as of December 31, 2021. Our working capital was $19.3 million and $18.0 million as of March 31, 2022 and December 31, 2021, respectively.

 

Net cash used in operating activities was approximately $1.0 million in 2022-Q1, an increase of cash used in operating activities of approximately $1.0 million compared to 2021-Q1. The increase in cash outflow was due to (a) a negative change in operating assets and liabilities of $0.5 million, (b) a decrease in non-cash charges by $0.2 million and (c) an increase in net loss by $0.3 million.

 

Net cash provided by investing activities was $1.8 million in 2022-Q1 compared to net cash used in investing activities of $1.7 million in 2021-Q1, a change in cash flow of $3.4 million. The change in cash flow was primarily due to (a) an increase in proceeds from sale of marketable securities net of any purchases from $0.1 million in 2021-Q1 to $2.0 million in 2022-Q1, and (b) a decrease in capitalized patent defense costs by $1.5 million.


Net cash used in financing activities in 2022-Q1 was $0.4 million consisting primarily of repayment of principal amounts due on senior convertible notes and Paycheck Protection Program Loans compared to cash used in financing activities of $86 thousand in 2021-Q1, which consisted primarily of repayment of principal amounts due on senior convertible notes.  

 

Capitalization of patent defense costs. We capitalize external legal costs incurred in the defense of our patents when we believe that a significant, discernible increase in value will result from the defense and a successful outcome of the legal action is probable. When we capitalize patent defense costs we amortize the costs over the remaining estimated useful life of the patents, which is 15 to 17 years. During 2022-Q1 we spent $0.2 million on legal costs related to the defense of our patents and capitalized the entire amount.

 

We are currently pursuing all available legal remedies to defend our strategic patents from infringement. We have already spent approximately $28.3 million from 2016 through March 31, 2022 towards this litigation and may be required to spend more to continue our legal defense. We believe the decision by the U.S. District Court in August 2019 granting our request for a preliminary injunction to prevent our competitor from manufacturing, marketing, and selling its competing ceiling microphone array in an infringing configuration is an incredibly valuable ruling for ClearOne and its business. We believe that the decision validates the strength and importance of ClearOne’s intellectual property rights, recognizes ClearOne’s innovations in this space, and stops our competitor from further infringing our Graham patent (U.S. Patent No. 9,813,806) pending a full trial. Although there can be no assurance of any outcome of a full trial, we believe this ruling will help pave way for ClearOne’s recovery from the immense harm inflicted by our competitor's infringement of our valuable patents. However, we are not getting the full benefits of the Court’s extraordinary remedy in the form of the preliminary injunction granted against Shure with respect to infringement of our ’806 Patent as we believe that Shure is still infringing ClearOne’s patent. During September 2020, the U.S District Court of Northern Illinois held Shure in contempt for marketing and selling their new design in violation of the preliminary injunction.

 

We have been actively engaged in preserving cash by suspending our dividend program and allowing our share repurchase program to expire in 2018 and implementing company-wide cost reduction measures. We have also raised additional capital of $9.9 million (net of issuance costs) in 2018 by issuing common stock, $2.7 million (net of issuances costs) in 2019 by issuing senior convertible notes, $1.5 million in April 2020 by borrowing through Paycheck Protection Program, $4.8 million (net of issuances costs) in September 2020 by issuing common stock and warrants, $2.0 million in July 2021 by issuing short-term debt which repaid through issue of common stock in January 2022, and $9.3 million (net of issuances costs) in September 2021 by issuing common stock and warrants. 


We also believe that our core strategies of product innovation and prudent cost management will bring us back to profitability in the future. We believe, although there can be no assurance, that all of these measures and effective management of working capital will provide the liquidity needed to meet our operating needs through at least through May 19, 2023. We also believe that our strong portfolio of intellectual property and our solid brand equity in the market will enable us to raise additional capital if and when needed to meet our short and long-term financing needs; however, there can be no assurance that, if needed, we will be successful in obtaining the necessary funds through equity or debt financing. If we need additional capital and are unable to secure financing, we may be required to further reduce expenses, delay product development and enhancement, or revise our strategy regarding ongoing litigation. 


As of March 31, 2022, we had open purchase orders of approximately $4.8 million mostly for purchase of inventory.

 

As of March 31, 2022, we had inventory totaling $13.1 million, of which non-current inventory accounted for $3.2 million. This compares to total inventories of $13.6 million and non-current inventory of $3.6 million as of December 31, 2021.